InjectionClinical Overview
Etophylline (84.7mg) and Theophylline (25.3mg per ml) Injection (Deriphyllin) is a parenteral methylxanthine bronchodilator combination on the WHO Model List framework. It non-selectively inhibits phosphodiesterase (PDE) enzymes, elevating intracellular cyclic AMP, competitively antagonizes adenosine A1 and A2 receptors, and stimulates endogenous catecholamine release. This produces relaxation of bronchial smooth muscle, stimulates the medullary respiratory center, improves diaphragmatic contractility, and exerts mild diuresis. Indicated for acute relief of severe bronchospasm in bronchial asthma, status asthmaticus, chronic bronchitis, and left ventricular failure with pulmonary edema (cardiac asthma).
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Administer by slow intravenous injection over at least 5 to 10 minutes, or as an IV infusion in 5% Dextrose or 0.9% NaCl. Slow IV injection is critical to prevent sudden fatal arrhythmias or convulsions. Adult dose: 2 mL slow IV, repeated up to 2 to 3 times daily as needed.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Nausea, vomiting, tachycardia, palpitations, headache, insomnia, tremors, flushing. Rare/Severe: Fatal ventricular arrhythmias, hypotension/cardiac arrest (with rapid IV push), and generalized seizures.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Inject slowly IV over >5-10 minutes. Extremely narrow therapeutic window (serum theophylline target: 10-20 mcg/mL); toxicities occur rapidly above 20 mcg/mL. Contraindicated in coronary artery disease, uncontrolled arrhythmias, active peptic ulcer, and severe hepatic impairment.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, pulmonological diagnosis, or respiratory management recommendations. Inhalation therapies and allergy medications should be used strictly under the guidance of a qualified pulmonologist or registered medical practitioner.
Etophyllin 77mg + Theophylline 23mg Tablets
Etophylline and Theophylline Tablets (77mg/23mg, 115mg/35mg PR, 231mg/69mg PR, 400mg Theophylline PR) is an oral methylxanthine bronchodilator on the WHO Model List of Essential Medicines. Etophylline enhances the water solubility and gastric tolerance of theophylline. Inhibits phosphodiesterase and antagonizes adenosine receptors to provide continuous bronchodilation and enhance diaphragmatic muscle endurance. Indicated for long-term maintenance of reversible bronchospasm in bronchial asthma, chronic bronchitis, and COPD.
Etophylline 115mg + Theophylline 35mg Prolonged Release Tablets
Etophylline and Theophylline Tablets (77mg/23mg, 115mg/35mg PR, 231mg/69mg PR, 400mg Theophylline PR) is an oral methylxanthine bronchodilator on the WHO Model List of Essential Medicines. Etophylline enhances the water solubility and gastric tolerance of theophylline. Inhibits phosphodiesterase and antagonizes adenosine receptors to provide continuous bronchodilation and enhance diaphragmatic muscle endurance. Indicated for long-term maintenance of reversible bronchospasm in bronchial asthma, chronic bronchitis, and COPD.
Etophylline 231mg + Theophylline 69mg Prolonged Release Tablets
Etophylline and Theophylline Tablets (77mg/23mg, 115mg/35mg PR, 231mg/69mg PR, 400mg Theophylline PR) is an oral methylxanthine bronchodilator on the WHO Model List of Essential Medicines. Etophylline enhances the water solubility and gastric tolerance of theophylline. Inhibits phosphodiesterase and antagonizes adenosine receptors to provide continuous bronchodilation and enhance diaphragmatic muscle endurance. Indicated for long-term maintenance of reversible bronchospasm in bronchial asthma, chronic bronchitis, and COPD.
Theophylline Prolonged-release Tablets 400 mg
Etophylline and Theophylline Tablets (77mg/23mg, 115mg/35mg PR, 231mg/69mg PR, 400mg Theophylline PR) is an oral methylxanthine bronchodilator on the WHO Model List of Essential Medicines. Etophylline enhances the water solubility and gastric tolerance of theophylline. Inhibits phosphodiesterase and antagonizes adenosine receptors to provide continuous bronchodilation and enhance diaphragmatic muscle endurance. Indicated for long-term maintenance of reversible bronchospasm in bronchial asthma, chronic bronchitis, and COPD.